HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer

被引：0

作者：

Sawada, Kentaro ^{[1
]}

Kawamoto, Yasuyuki ^{[2
]}

Yuki, Satoshi ^{[3
]}

Nakamura, Michio ^{[4
]}

Muto, Osamu ^{[5
]}

Sogabe, Susumu ^{[6
]}

Shindo, Ysohiaki ^{[7
]}

Ishiguro, Atsushi ^{[8
]}

Sato, Atsushi ^{[9
]}

Tsuji, Yasushi ^{[10
]}

Dazai, Masayoshi ^{[11
]}

Okuda, Hiroyuki ^{[12
]}

Sasaki, Takahide ^{[13
]}

Harada, Kazuaki ^{[2
]}

Nakano, Shintaro ^{[2
]}

Nakatsumi, Hiroshi ^{[3
]}

Sekiguchi, Mari ^{[14
]}

Sakata, Yuh ^{[15
]}

Sakamoto, Naoya ^{[3
]}

Komatsu, Yoshito ^{[2
]}

机构：

[1] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Japan

[2] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[4] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[5] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan

[6] KKR Sapporo Med Ctr, Dept Med Oncol, Sapporo, Hokkaido, Japan

[7] Nakadori Gen Hosp, Dept Surg, Akita, Japan

[8] Teine Keijinkai Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[9] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

[10] Tonan Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[11] Sapporo Med Ctr NTT EC, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[12] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[13] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[14] Hokkaido Gastrointestinal Canc Study Grp, Data Ctr, Sapporo, Hokkaido, Japan

[15] Misawa City Hosp, Misawa, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.628

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO26-5

引用

页码：S314 / S314

页数：1

共 50 条

[41] Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601)
Sato, Sho
Kunisaki, Chikara
Tamura, Yuko
Yago, Akikazu
Kasahara, Kohei
Sato, Tsutomu
Kondo, Hiroki
Kosaka, Takashi
Akiyama, Hirotoshi
Endo, Itaru
ANTICANCER RESEARCH, 2023, 43 (12) : 5663 - 5669
[42] Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Liuting Yang
Xiaoyue Jiang
Han Yan
Yingying Li
Hongchao Zhen
Bingmei Chang
Seyed Kariminia
Qin Li
BMC Gastroenterology, 18
[43] Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen
Schüll, B
Kornek, GV
Schmid, K
Raderer, M
Ulrich-Pur, H
Fiebiger, W
Schneeweiss, B
Lenauer, A
Depisch, D
Scheithauer, W
ONKOLOGIE, 2002, 25 (04): : 358 - 362
[44] Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Yang, Liuting
Jiang, Xiaoyue
Yan, Han
Li, Yingying
Zhen, Hongchao
Chang, Bingmei
Kariminia, Seyed
Li, Qin
BMC GASTROENTEROLOGY, 2018, 18
[45] A pilot study of Irinotecan plus raltitrexed as second-line treatment for advanced colorectal cancer.
Qu, Xiujuan
Wu, Zhenhai
Wang, Shuo
Qu, Jinglei
Zhang, Lingyun
Liu, Jing
Shi, Jing
Zhang, Jingdong
Liu, Yunpeng
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Differences in efficacy of biweekly irinotecan plus cisplatin versus irinotecan alone in second-line treatment of advanced gastric cancer with or without prior gastrectomy
Nishikawa, Kazuhiro
Koizumi, Wasaburo
Tsuburaya, Akira
Suzuki, Motoko
Morita, Satoshi
Fujitani, Kazumasa
Akamaru, Yusuke
Shimada, Ken
Hosaka, Hisashi
Nishimura, Ken
Yoshikawa, Takaki
Tsujinaka, Toshimasa
Sakamoto, Junichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 320 - 329
[47] BIWEEKLY COMBINATION CHEMOTHERAPY OF DOCETAXEL, IRINOTECAN AND CISPLATIN AS SECOND-LINE TREATMENT FOR ADVANCED GASTRIC CANCER
Denda, T.
Sudo, K.
Nakamura, K.
Hara, T.
Yamaguchi, T.
ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
[48] A case report of four patients received ramucirumab monotherapy as second-line treatment for advanced gastric cancer
Onodera, Kei
Ichiyanagi, Akiko
Ueno, Akari
Tani, Motohiro
Sato, Shuji
Shimizu, Haruo
Kaneto, Hiroyuki
ANNALS OF ONCOLOGY, 2021, 32 : S353 - S353
[49] Fractional weekly administration of irinotecan and cisplatin as a second-line treatment for advanced gastric cancer.
Jeung, HC
Noh, SH
Lee, JI
Chung, HC
Rha, SY
Roh, JK
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 327S - 327S
[50] Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)
Ramaswamy, Anant
Ostwal, Vikas
Sharma, Atul
Bhargava, Prabhat
Srinivas, Sujay
Goel, Mahesh
Patkar, Shraddha
Mandavkar, Sarika
Jadhav, Poonam
Parulekar, Manali
Choudhari, Amitkumar
Gupta, Sudeep
JAMA ONCOLOGY, 2021, 7 (03) : 436 - 439

← 1 2 3 4 5 →